# To Demonstrate the Relative Bioavailability of Atenolol Tablets

> **NCT00913965** · PHASE1 · COMPLETED · sponsor: **Sandoz** · enrollment: 24 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Atenolol Tablets 100 mg (Cord Laboratories)
- **DRUG:** Atenolol Tablets 100 mg (Stuart Pharmaceutical)

## Key facts

- **NCT ID:** NCT00913965
- **Lead sponsor:** Sandoz
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1989-07
- **Primary completion:** 1989-08
- **Final completion:** 1989-08
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00913965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00913965, "To Demonstrate the Relative Bioavailability of Atenolol Tablets". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00913965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*